Claims for Patent: 6,046,178

Summary for Patent: 6,046,178

Title:	Method and compound for treating wounds with starch hydrolysate medication
Abstract:	A medication and method for treating wounds by contacting the wound, for a sufficient period of time, with a therapeutically effective amount of a starch hydrolysate composition including trace elements, to beneficiate the wound healing processes. A possible starch hydrolysate is maltodextrin and possible trace elements include, at least copper and zinc. The composition may also contain ascorbic acid as well as antibacterial and nutritive agents to promote formation and growth of granulation tissue.
Inventor(s):	Silvetti, Sr.; Anthony N. (River Forest, IL)
Assignee:	DeRoyal Industries, Inc. (Powell, TN)
Application Number:	08/844,240
Patent Claims:	1. A method of treating a wound in a patient, the method comprising contacting the wound, for a period of time sufficient to initiate wound healing, with a therapeutically effective amount of a gel composition, the gel comprising a continuous phase of starch hydrolysate, sterile water, and a dispersed phase of a gelatinization agent, and wherein the composition has a viscosity between 29,000 and 37,000 centipoise. 2. The method of claim 1, further comprising a trace amount of metal. 3. The method of claim 2, wherein said starch hydrolysate has a dextrose equivalent of not more than 30. 4. The method of claim 1, wherein said starch hydrolysate has a dextrose equivalent of not more than 30. 5. The method of claim 4, wherein said starch hydrolysate is a maltodextrin having a dextrose equivalent of between about 13 and about 17. 6. The method of claim 1, wherein said gelatinization agent is glycerin. 7. The method of claim 2, wherein the metal comprises copper or a pharmaceutically acceptable salt thereof. 8. The method of claim 2, wherein the metal comprises zinc or a pharmaceutically acceptable salt thereof. 9. The method of claim 1, wherein the composition further comprises an antibacterial agent and a nutritive agent, whereby to promote formation and growth of granulation tissue. 10. The method of claim 1, wherein the composition further comprises a monosaccharide, whereby to accelerate revascularization, development of granulation tissue, and wound closure. 11. The method of claim 1, wherein the composition further comprises one or more amino acids, whereby to improve healing. 12. A method of treating a wound in a patient, the method comprising the step of contacting said wound, for a period of time sufficient to initiate wound healing, with a therapeutically effective amount of a gel composition, the gel comprising a continuous phase of maltodextrin, sterile water, at least one metal, and a dispersed phase of glycerin, and the gel having a viscosity between 29,000 and 37,000 centipoise. 13. The method of claim 12, wherein the metal comprises copper or a pharmaceutically acceptable salt thereof. 14. The method of claim 12, wherein the metal comprises zinc or a pharmaceutically acceptable salt thereof. 15. The method of claim 12, wherein the composition further comprises an antibacterial agent and a nutritive agent, whereby to promote formation and growth of granulation tissue. 16. The method of claim 12, wherein the composition further comprises monosaccharide, whereby to accelerate revascularization, development of granulation tissue, and wound closure. 17. The method of claim 12, wherein the composition further comprises one or more amino acids, whereby to improve healing. 18. A method for treating a wound in a patient, the method comprising steps of: providing a gel composition comprising a viscous, continuous phase starch hydrolysate mixture having a dispersed phase of a gelatinization agent with a viscosity between 29,000 and 37,000 centipoise; and spreading a therapeutically effective amount of the gel composition on the wound for a sufficient period of time to initiate wound healing. 19. The method of claim 18, wherein the starch hydrolysate mixture has a dextrose equivalent of not more than 30. 20. The method of claim 19, wherein the gel composition further includes ascorbic acid and at least one amino acid, whereby to improve healing. 21. The method of claim 20, further including an antibacterial, nutritive agent to promote forming and growth of granulation tissue, and a starch hydrolysate having a dextrose equivalent between 13 and 17. 22. A gel composition for treating a wound in a patient, the gel composition comprising a continuous phase of starch hydrolysate and sterile water and a dispersed phase of gelatinization agent, said starch hydrolysate having a dextrose equivalent of not more than 30, and having a viscosity between 29,000 and 37,000 centipoise. 23. The gel composition of claim 22, wherein said starch hydrolysate is a maltodextrin having a dextrose equivalent of between about 13 and about 17. 24. The gel composition of claim 22, wherein said gelatinization agent is glycerin. 25. The gel composition of claim 22, wherein said gel composition further comprises ascorbic acid or a pharmaceutically acceptable salt thereof. 26. The gel composition of claim 22, wherein said gel composition further comprises an antibacterial agent and a nutritive agent, whereby to promote formation and growth of granulation tissue. 27. The gel composition of claim 22, wherein said gel composition further comprises a monosaccharide, whereby to accelerate revascularization, development of granulation tissue, and wound closure. 28. The gel composition of claim 22, wherein said gel composition further comprises one or more amino acids, whereby to improve healing. 29. A gel composition for treating a wound in a patient, the gel composition having a continuous phase of starch hydrolysate, sterile water, and a dispersed phase of glycerin and includes ascorbic acid, and an antibacterial agent, nutritive agent, a monosaccharide, and at least one amino acid, whereby to accelerate revascularization, development of granulation tissue, and wound closure, and wherein the composition has a viscosity between 29,000 and 37,000 centipoise. 30. The gel composition of claim 29, wherein the starch hydrolysate is a maltodextrine having a dextrose equivalent of between about 13 and about 17.

Details for Patent 6,046,178

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-23